Sun maintained it would retain the best of both organisations to build a global pharma company.
A source said the competition watchdog would by next month suggest 'structural remedies' that included selling key drug segments as conditions for clearing the country's largest pharmaceutical industry merger.
US country head, key departmental heads leave; more likely to follow.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
May invest around $100 mn in setting up a 200-acre park
No Ebola case detected in the country so far; experts say a robust preparedness plan to fight the virus missing.
Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months
Industry insiders expect Chinese tourists coming to India to double in around two years.
Proposed investment dip 33% from Rs 1.42 lakh crore (Rs 1.42 trillion) in 2011 to Rs 94,259 crore (Rs 942.59 billion) in 2013
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
The idea is to keep a close watch on real-time price movements, the maximum retail price of medicines and their availability.
Twenty-year-old Ripal Prajapati had to settle for mailing a 'rakhi' to her god-brother this time around.
.jpg)
The creation of the Amul brand and its famous mascot gave a rural revolution a durable competitive edge.
The Ministry of Science and Technology has approached about a dozen well-known scientists from across the world in an effort to bring them back to various departments under the ministry, said Jitendra Singh, minister of state (independent charge) for science and technology.
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
Slapped with Rs 242-crore fine by US authorities for rule violations at Toansa unit, say sources; 2nd such hefty rap in the recent past from US regulators for bending rules.
Sun Pharma to retain these in most markets; US could be the exception, where the Ranbaxy name has taken a hit.
Altaf Ahmed Lal, country head of the US Food and Drug Administration (US FDA) in India, has quit and so have a few other key officials at the American drug regulator's India office.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances